Analyst Price Targets — ORGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 10:13 am | — | UBS | $3.00 | $2.66 | TheFly | Organogenesis initiated with a Hold at Truist |
| May 28, 2026 10:06 am | Ravi Misra | Truist Financial | $3.00 | $2.66 | StreetInsider | Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold |
| November 20, 2025 12:10 pm | — | BTIG | $9.00 | $5.14 | TheFly | Organogenesis price target raised to $9 from $7 at BTIG |
| March 5, 2025 12:21 pm | — | Morgan Stanley | $6.00 | $6.01 | TheFly | Organogenesis price target raised to $6 from $4 at Morgan Stanley |
| June 28, 2024 8:01 am | Brooks O'Neil | Lake Street | $5.00 | $2.64 | TheFly | Organogenesis initiated with a Buy at Lake Street |
Latest News for ORGO
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the…
CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepted for review the Company's Biologics License Application (BLA) for…
Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges.
Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare policy changes and related commentary from the Centers for Medicare & Medicaid Services (CMS).
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORGO.
U.S. House Trading
No House trades found for ORGO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.